Evidence map›Paper›PMID 36523401›Full record

ArticlebioRxiv : the preprint server for biology2022

Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance.

Timothy R O'Meara, Etsuro Nanishi, Marisa E McGrath, Soumik Barman, Danica Dong, Carly Dillen, Manisha Menon, Hyuk-Soo Seo, Sirano Dhe-Paganon, Robert K Ernst and 3 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Timothy R O'MearaPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 02115.
Etsuro NanishiPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 02115.
Marisa E McGrathCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA 21201.
Soumik BarmanPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 02115.
Danica DongPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 02115.
Carly DillenCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA 21201.
Manisha MenonPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 02115.
Hyuk-Soo SeoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA 02115.
Sirano Dhe-PaganonDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA 02115.
Robert K ErnstDepartment of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA 21201.
Ofer LevyPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 02115.
Matthew B FriemanCenter for Pathogen Research, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA 21201.
David J DowlingPrecision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA 02115.
Boston Children's Hospital · USUniversity of Maryland, Baltimore · USHarvard University · USBroad Institute · US

Funding

Small-molecule adjuvants to enhance the efficacy of flu vaccines in newborns and the elderly75N93019C00044 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2019 to 2023
$11.0M
Role of Diabetes in MERS Coronavirus PathogenesisR01AI148166 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI FRIEMAN, MATTHEW BRYAN · 2020 to 2023
$2.3M
Leveraging immunostimulatory pathways that enhance BCG vaccination for the rational design of synthetic neonatal vaccine formulationsR21AI137932 · NIAID · NORTHWESTERN UNIVERSITY · PI DOWLING, DAVID JAMES, SCOTT, EVAN ALEXANDER · 2019 to 2020
$468k
NIAID NIH HHS 75N93019C00044NIAID NIH HHS HHSN272201400007CNIAID NIH HHS HHSN272201400052CNIAID NIH HHS HHSN272201800047CNIAID NIH HHS R01 AI148166NIAID NIH HHS R21 AI137932
6 · The paper itself

Abstract

Background: Obesity and Type 2 Diabetes Mellitus (T2DM) are associated with an increased risk of severe outcomes from infectious diseases, including COVID-19. These conditions are also associated with distinct responses to immunization, including an impaired response to widely used SARS-CoV-2 mRNA vaccines. Objective: To establish a connection between reduced immunization efficacy via modeling the effects of metabolic diseases on vaccine immunogenicity that is essential for the development of more effective vaccines for this distinct vulnerable population. Methods: We utilized a murine model of diet-induced obesity and insulin resistance to model the effects of comorbid T2DM and obesity on vaccine immunogenicity and protection. Results: Mice fed a high-fat diet (HFD) developed obesity, hyperinsulinemia, and glucose intolerance. Relative to mice fed a normal diet (ND), HFD mice vaccinated with a SARS-CoV-2 mRNA vaccine exhibited significantly lower anti-spike IgG titers, predominantly in the IgG2c subclass, associated with a lower type 1 response, along with a 3.83-fold decrease in neutralizing titers. Furthermore, enhanced vaccine-induced spike-specific CD8 Conclusion: We demonstrate impaired immunity following SARS-CoV-2 mRNA immunization in a murine model of comorbid T2DM and obesity, supporting the need for further research into the basis for impaired anti-SARS-CoV-2 immunity in T2DM and investigation of novel approaches to enhance vaccine immunogenicity among those with metabolic diseases. Capsule summary: Obesity and type 2 diabetes impair SARS-CoV-2 mRNA vaccine efficacy in a murine model.

Identifiers

PMID36523401
PMCPMC9753785
OpenAlexW4311843318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.